Pulmonx Company (NASDAQ:LUNG) is likely one of the finest shares underneath $3 to spend money on. On October 28, Lake Avenue lowered the agency’s worth goal on Pulmonx to $4 from $8 and stored a Purchase ranking on the shares.
The agency believes that Wall Avenue will view the return of former CEO Glen French and CFO Derrick Sung positively. The shares are enticing as a result of huge medical proof of idea of Zephyr valves, the robust market alternative, and the brand new product pipeline.
On the identical day, Stifel Nicolaus analyst Rick Smart maintained a Purchase ranking on Pulmonx and set a worth goal of $5.00. Moreover, John Younger CFA from Canaccord Genuity maintained a Purchase ranking on Pulmonx, with a worth goal of $6.00.
Pulmonx Company (NASDAQ:LUNG) is a commercial-stage medical expertise firm that gives a minimally invasive remedy for sufferers with extreme emphysema, a type of continual obstructive pulmonary illness.
Whereas we acknowledge the potential of LUNG as an funding, we imagine sure AI shares provide higher upside potential and carry much less draw back danger. In case you’re searching for a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the finest short-term AI inventory.
READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase Proper Now.
Disclosure: None. This text is initially revealed at Insider Monkey.
